Article Details
Retrieved on: 2024-07-24 10:57:13
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article highlights a collaboration between Insilico Medicine and Therasid Bioscience to develop therapies for metabolic dysfunction-associated steatohepatitis (MASH) using AI technology. It emphasizes epidemiological challenges in diagnosing and treating liver diseases like MASH, which can progress to serious conditions such as cirrhosis and liver cancer.
Article found on: www.eurekalert.org
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here